Ambitiøs biotekfond lukker ned før første investering

Ambitionerne var store, da Sund Capital med tidligere Zealand Pharma-direktør David Solomon i spidsen, annoncerede, at man ville rejse op mod to mia. kr. til investeringer i lovende biotekselskaber. Nu lukker fonden ned.
Photo: /ritzau scanpix/Søren Bidstrup
Photo: /ritzau scanpix/Søren Bidstrup

Med et tab på samlet 2,9 mio. kr. efter halvandets års drift bliver der nu sat punktum for investeringsfonden Sund Capital, der i sommeren 2016 blev sat i verden med ambition om at investere op mod 2,2 mia. kr. i nordiske biotekselskaber.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading